 |
| |
| Feb-27-20 | Upgrade |
Standpoint Research |
Hold → Buy |
|
|
| Feb-27-20 | Initiated |
Barclays |
Equal Weight |
$36 |
|
| Feb-06-20 | Initiated |
Mizuho |
Buy |
|
|
| Jan-07-20 | Initiated |
RBC Capital Mkts |
Outperform |
$46 |
|
| Oct-17-19 | Resumed |
BofA/Merrill |
Neutral |
$37 |
|
| Jul-30-19 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
$48 → $40 |
|
| Jul-30-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Jun-04-19 | Resumed |
Morgan Stanley |
Overweight |
$48 |
|
| Feb-20-19 | Resumed |
Citigroup |
Neutral |
$41 |
|
| Jan-31-19 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
| Jan-31-19 | Upgrade |
Argus |
Hold → Buy |
|
|
| Jan-23-19 | Downgrade |
UBS |
Buy → Neutral |
|
|
| Dec-11-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Nov-01-18 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
|
|
| Jun-08-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$45 |
|
| Apr-05-18 | Downgrade |
Barclays |
Overweight → Equal Weight |
$41 → $38 |
|
| Jan-29-18 | Reiterated |
SunTrust |
Hold |
$33 → $40 |
|
| Sep-20-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Jul-20-17 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| May-16-17 | Downgrade |
Citigroup |
Neutral → Sell |
|
|
|
|
| May-27-20 03:49AM | Pharma exports a rare bright spot for Singapore economy as pandemic drives demand Reuters |
| May-26-20 02:03PM | Hedge Funds Are Warming Up To Pfizer Inc. (PFE) Insider Monkey |
| 01:47PM | Coronavirus update: Novavax begins vaccine trials; Brazil reports second-highest number of cases in world Yahoo Finance |
| 11:53AM | Novavax expects COVID-19 vaccine trial results in July Yahoo Finance |
| 10:54AM | Anti-anxiety medication prescriptions have spiked 34% during the coronavirus pandemic MarketWatch |
| 10:52AM | The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline Zacks |
| 10:13AM | Merck Dives Into Covid-19 Fray With Two Vaccines and One Antiviral Barrons.com |
| 09:59AM | Novavax and Merck Fuel COVID-19 Vaccine Hopes Investopedia |
| 09:39AM | Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial Zacks |
| 08:00AM | Pfizer Is Charging Ahead With A Coronavirus Vaccine Is PFE Stock A Buy? Investor's Business Daily |
| 08:00AM | AbbVie Wrapped Its $63 Billion Allergan Buyout Is AbbVie Stock A Buy? Investor's Business Daily |
| 07:30AM | ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc. GlobeNewswire |
| May-24-20 08:21AM | An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race Yahoo Finance |
| 07:33AM | 3 Large-Cap Coronavirus Stocks Still Worth Buying Motley Fool |
| May-23-20 09:15AM | Some wellness products growing over 1,000% during pandemic: Ro CEO Yahoo Finance |
| May-22-20 04:30PM | Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC Business Wire |
| 04:26PM | Coronavirus latest: Friday, May 22 Yahoo Finance Video |
| 11:50AM | Is Pfizer (PFE) a Great Value Stock Right Now? Zacks |
| 09:22AM | The race for a coronavirus treatment is fanning fears of 'vaccine nationalism' Yahoo Finance Video |
| 07:46AM | Telehealth is going to 'become the default' for patients: Ro CEO Yahoo Finance |
| 07:29AM | Everything you need to know about the Oxford University vaccine and other efforts to beat coronavirus MarketWatch |
| 06:16AM | The race for a coronavirus treatment is fanning fears of 'vaccine nationalism' Yahoo Finance |
| 05:37AM | Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales Zacks |
| 02:51AM | Coronavirus Vaccine Race Pushes Up Pharma Giants' Production Zacks |
| May-21-20 03:48PM | Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video |
| 10:46AM | For Moderna, a Coronavirus Vaccine Would Be the Tip of the Iceberg Barrons.com |
| 04:22AM | AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer Zacks |
| May-20-20 04:50PM | Pfizer Participates in Funding for Biotech Startup Amplyx Motley Fool |
| 04:30PM | FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck Motley Fool |
| 12:00PM | GSK ties up with gene editing start-up Mammoth for COVID-19 test Reuters |
| 11:52AM | Sorrento Therapeutics CEO: We are not a 'pump and dump' scheme Yahoo Finance |
| 08:11AM | Better Buy: GlaxoSmithKline vs. Pfizer Motley Fool |
| 06:42AM | J&J to Stop Sale of Talc-Based Baby Powder in North America Zacks |
| May-19-20 03:18PM | Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' Yahoo Finance Video |
| 02:59PM | GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada Motley Fool |
| 11:39AM | Glaxo's Long-Acting HIV Injection Effective Than Daily Pills Zacks |
| 11:39AM | A Covid-19 Vaccine Could Be Worth Billions for Moderna and Its Rivals Barrons.com |
| 08:11AM | Pfizer Seeks To Raise $4 Billion From Debt Sale SmarterAnalyst |
| 06:04AM | What's Behind Axsome Therapeutics' Miracle Pipeline? Motley Fool |
| 05:52AM | Market pros have high hopes for a COVID-19 vaccine: Morning Brief Yahoo Finance |
| May-18-20 09:24PM | Pfizer Prices $4,000,000,000 Debt Offering Business Wire |
| 02:54PM | We anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist Yahoo Finance Video |
| 02:47PM | Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video |
| 02:05PM | Heres what it will take for the stock market to hit a new record within 2 months MarketWatch |
| 12:27PM | Moderna Soars: Biotech ETFs in Focus Zacks |
| 11:52AM | Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; on review for downgrade Moody's |
| 11:38AM | Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data Zacks |
| 11:20AM | Who Is Winning the COVID-19 Vaccine Race? Investopedia |
| 10:49AM | Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy Zacks |
| 02:29AM | Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pill MarketWatch |
| May-17-20 02:03PM | Better Buy: Pfizer vs. Bristol Myers Squibb Motley Fool |
| May-16-20 03:10PM | Economic expert with perfect record calling recessions is betting this one will be over by the end of 2020 MarketWatch |
| 07:21AM | Can Pfizer's Stock Keep Climbing? Motley Fool |
| May-15-20 04:15PM | Why Sarepta Has A Leg Up On Pfizer With A Rival Gene Therapy: Analysts Investor's Business Daily |
| 03:37PM | Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics Motley Fool |
| 03:09PM | Trump unveils vaccine effort, says country will be back on its feet with or without one Yahoo Finance Video |
| 10:03AM | Sarepta Gains After Pfizer DMD Gene Therapy Data Fall Short Bloomberg |
| 08:01AM | Pfizer to launch late stage DMD gene therapy trial despite hospitalizations Reuters |
| 08:00AM | Pfizers New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study Business Wire |
| May-14-20 02:01PM | The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY Zacks |
| 11:51AM | Coronavirus Vaccine Progress Accelerates Yahoo Finance |
| 11:33AM | Three Dividend Growth Stocks We Recently Purchased for Our Portfolio GuruFocus.com |
| 11:16AM | Relaxing the Lockdown: Move Slowly, Stay Nimble Yahoo Finance |
| 10:00AM | Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age Business Wire |
| May-13-20 10:00AM | Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day Business Wire |
| 09:34AM | Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks Zacks |
| 08:16AM | Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners Zacks |
| 03:43AM | Pfizer Plans To Test Covid-19 Vaccine On Thousands Of Patients By September- Report SmarterAnalyst |
| 02:18AM | Pfizer Plans To Test Coronavirus Vaccine On Thousands Of Patients By September Benzinga |
| May-12-20 05:07PM | Hedge Fund Tells Alexion Management to Sell Company GuruFocus.com |
| 04:24PM | MEDIA-Pfizer wants to expand human trials of coronavirus vaccine to thousands of people by September - CNBC Reuters |
| 12:00PM | New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program Business Wire |
| 10:00AM | Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire |
| 07:52AM | Sarepta Investors Buckle Up for Pfizers DMD Gene Therapy Update Bloomberg |
| May-11-20 05:40PM | US Indexes Post Some Gains Monday GuruFocus.com |
| 04:51PM | Dow ends 100 points lower, leaving stock benchmarks mixed amid skepticism over re-openings MarketWatch |
| 01:12PM | Health-care ETFs rise as coronavirus treatments take center stage MarketWatch |
| 10:53AM | Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling Zacks |
| 08:50AM | Mylan's stock gains 2%; guidance for 2020 reaffirmed MarketWatch |
| 08:27AM | Mylan first-quarter revenue jumps 5% on drug stockpiling Reuters |
| May-10-20 09:15AM | Is There A Safer Way to Invest in a Coronavirus Vaccine? Motley Fool |
| 07:33AM | How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal? Motley Fool |
| 02:26AM | Pfizer Sets Wheels In Motion For Covid-19 Vaccine Production Ramp SmarterAnalyst |
| May-09-20 01:23PM | Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine Motley Fool |
| May-08-20 06:55PM | Pfizer to outsource some drug production, focus on coronavirus vaccine Reuters |
| 06:40PM | Pfizer to outsource some drug production, focus on coronavirus vaccine Reuters |
| 04:59PM | Stocks jump despite a record 20.5M jobs lost in April Yahoo Finance Video |
| 04:53PM | This PayPal Options Move Is Better Than Cash Barrons.com |
| 02:30PM | ICU Medical Inc (ICUI) Q1 2020 Earnings Call Transcript Motley Fool |
| 11:04AM | Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY Zacks |
| 10:29AM | Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates Zacks |
| 10:00AM | Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting Business Wire |
| May-07-20 05:45PM | The Dow Rose 211 Points Because Coronavirus Vaccines and Trade Talks Look Possible Barrons.com |
| 05:07PM | Here's Why OPKO Health Shares Tumbled 16.7% Today Motley Fool |
| 04:56PM | Dow ends up 211 points but gains were cut in half headed into the close as Pfizers stock slump weighed MarketWatch |
| 03:11PM | Coronavirus update: US jobless numbers amplify reopening debate; US, NY case split grows Yahoo Finance |
| 02:45PM | Stocks surge despite another grim jobless claims report Yahoo Finance Video |
| 11:15AM | Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates Zacks |
| 09:59AM | Dow Jones Today, Stocks Jump As Jobless Surge Slows: PayPal, Dexcom Lead; Moderna Vaccine Gets FDA Nod Investor's Business Daily |
| 09:59AM | The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi Zacks |
|
|
|
|
| Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Dolsten Mikael | President R&D | May 18 | Sale | 37.78 | 95,353 | 3,602,681 | 174,918 | May 19 05:37 PM | | DAMICO JENNIFER B. | SVP & Controller | Apr 29 | Sale | 38.35 | 2,181 | 83,641 | 9,647 | May 01 03:56 PM | | JOHNSON RADY A | Executive Vice President | Apr 29 | Sale | 38.36 | 13,125 | 503,475 | 63,940 | May 01 03:56 PM | | ROGERS DAWN | Executive Vice President | Apr 29 | Sale | 38.13 | 13,000 | 495,690 | 4,823 | May 01 03:56 PM | | LANKLER DOUGLAS M | Executive Vice President | Apr 29 | Sale | 37.85 | 65,000 | 2,460,372 | 78,276 | May 01 03:56 PM | | PFIZER INC | 10% Owner | Mar 16 | Buy | 16.00 | 312,500 | 5,000,000 | 1,481,719 | Mar 16 07:15 PM | | GOETTLER MICHAEL | Group President | Feb 28 | Option Exercise | 27.37 | 22,852 | 625,459 | 53,036 | Mar 03 12:54 PM | | JOHNSON RADY A | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 15,996 | 437,811 | 87,956 | Mar 03 12:54 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 38,848 | 1,063,270 | 172,542 | Mar 03 12:54 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 37,934 | 1,038,254 | 140,256 | Mar 03 12:54 PM | | ROGERS DAWN | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 17,824 | 487,843 | 30,045 | Mar 03 12:54 PM | | SUSMAN SALLY | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 91,408 | 2,501,837 | 222,496 | Mar 03 12:55 PM | | YOUNG JOHN D | Group President | Feb 28 | Option Exercise | 27.37 | 100,548 | 2,751,999 | 504,427 | Mar 03 12:55 PM | | BOURLA ALBERT | Chairman & CEO | Feb 28 | Option Exercise | 27.37 | 33,135 | 906,905 | 232,888 | Mar 03 12:49 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 28 | Option Exercise | 27.37 | 27,422 | 750,540 | 140,744 | Mar 03 12:49 PM | | DAMELIO FRANK A | Executive Vice President | Feb 28 | Option Exercise | 27.37 | 173,675 | 4,753,485 | 556,084 | Mar 03 12:49 PM | | YOUNG JOHN D | Group President | Feb 26 | Option Exercise | 34.59 | 144,928 | 5,013,060 | 503,738 | Feb 28 07:32 PM | | ROGERS DAWN | Executive Vice President | Feb 26 | Option Exercise | 34.59 | 15,097 | 522,205 | 24,995 | Feb 28 07:28 PM | | SUSMAN SALLY | Executive Vice President | Feb 26 | Option Exercise | 34.59 | 72,464 | 2,506,530 | 180,558 | Feb 28 07:28 PM | | JOHNSON RADY A | Executive Vice President | Feb 26 | Option Exercise | 34.59 | 33,414 | 1,155,790 | 93,211 | Feb 28 07:24 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 26 | Option Exercise | 34.59 | 88,567 | 3,063,533 | 189,936 | Feb 28 07:25 PM | | GOETTLER MICHAEL | Group President | Feb 26 | Option Exercise | 34.59 | 20,129 | 696,262 | 45,557 | Feb 28 07:22 PM | | Hwang Angela | Group President | Feb 26 | Option Exercise | 34.59 | 14,493 | 501,313 | 32,470 | Feb 28 07:22 PM | | DAMELIO FRANK A | Executive Vice President | Feb 26 | Option Exercise | 34.59 | 144,928 | 5,013,060 | 482,320 | Feb 28 07:19 PM | | BOURLA ALBERT | Chairman & CEO | Feb 26 | Option Exercise | 34.59 | 88,567 | 3,063,533 | 274,479 | Feb 28 07:16 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 26 | Option Exercise | 34.59 | 24,155 | 835,521 | 131,196 | Feb 28 07:15 PM | | Gottlieb Scott | Director | Jan 30 | Buy | 37.00 | 1,000 | 36,997 | 4,000 | Jan 31 08:06 AM | | PFIZER INC | 10% Owner | Sep 17 | Buy | 18.00 | 50,000 | 900,000 | 4,593,847 | Sep 19 04:19 PM | | Gottlieb Scott | Director | Aug 23 | Buy | 34.72 | 3,000 | 104,160 | 3,000 | Aug 26 09:27 AM | | DAMELIO FRANK A | Executive Vice President | Jul 02 | Sale | 44.09 | 153,184 | 6,753,385 | 337,392 | Jul 03 04:06 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Jun 20 | Sale | 44.00 | 30,000 | 1,320,000 | 80,094 | Jun 21 04:08 PM |
|
|
|
|
|
|
